Amyris, the U.S. industrial bioscience company led by John Melo, closed the second and final tranche of its previously announced financing. The second tranche of $50 million in a private placement was led by a $25 million investment from Koninklijke DSM N.V. (Royal DSM) with the remaining $25 million contributed by Vivo Capital.

Continue reading →